НАСЛЕДСТВЕННЫЕ БОЛЕЗНИ
ТЕРАПИЯ

(латиница)
P

PAIN CHRONIC
  • GENE THERAPY
      ◊CRISPR-Based Epigenome Editing of Cytokine Receptors
      ◊Gene therapy for chronic pain management
    • PANCREATIC CANCER
  • THERAPY
      ◊ Role of Exosomes
      ◊ Gene therapy for pancreatic cancer using non-viral nanovectors
  • PANCREATIC DUCTAL ADENOCARCINOMA
      ◊ Gene Therapy Using Nanocarriers for Pancreatic Ductal Adenocarcinoma PARKINSON's DISEASE
  • GENE THERAPY
      ◊ CRISPR-Cas Reveals Protective Genes against Alpha-Synuclein Toxicity
      ◊ Next-Generation Gene Therapy for Parkinson’s Disease Using Engineered Viral Vectors
      ◊ Safety of AADC Gene Therapy for Moderately Advanced Parkinson Disease
      ◊Shedding light on gene therapy of ParkinsonТs disease in non-human primates
      ◊Parkinsonаs Disease Using Midbrain Developmental Genes to Regulate Dopaminergic Neuronal Maintenance
  • AUTOSOMAL RECESSIVE JUVENILE PARKINSONISM(ARJP)
      ◊Cell division control related protein 1
  • GAD GENE THERAPY
      ◊glutamatergic neurotransmission
  • THERAPY
      ◊ Approaches
      ◊ Therapeutic Strategy in Experimental Models of Parkinson's Disease
      ◊ Targeted Therapies for Parkinson's Disease
      ◊ Genetic and Gene Therapy for Parkinson’s Disease
  • PARKINSONIAN RODENTS AND PRIMATES
      ◊ Glial cell line-derived neurotrophic factor
    • PELIZAEUS-MERZBACHER DISEASE
  • THERAPY
      ◊ Gene suppressing therapy for Pelizaeus-Merzbacher disease using artificial microRNA
    • PHENYLKETONURIA
  • GENE THERAPY
      ◊ CRISPR/Cas9 Gene Editing in Murine Phenylketonuria
    • PLASMA PROTEIN DEFICIENCY
  • GENE THERAPY
      ◊ Treatment of Plasma Protein Deficiency
    • POLYCYSTIC KIDNEY DISEASE
  • AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE
      ◊ Tolvaptan therapy
    • POLYGENIC OR COMPLEX DISEASES
  • GENE THERAPY
      ◊Gene therapy for polygenic or complex diseases
    • POLYGLUTAMINE SPINOCEREBELLAR ATAXIAS
  • GENE THERAPY
      ◊ Gene Therapy for Polyglutamine Spinocerebellar Ataxias: Advances, Challenges, and Perspectives
    • POLYGLUTAMINE AGGREGATION AND TOXICITY
  • CONTROL WITH CHAPERONIN TRiC
      ◊ Assembly nontoxic aggregates
    • POMPE DISEASE
  • GENOTHERAPY
      ◊ Gene Therapy Developments for Pompe Disease


    • PRADER-WILLI SYNDROME
  • PROTEIN THERAPY
      ◊ Zinc finger protein 274 regulates imprinted expression of transcripts
    • PRIME EDITING
  • PAIRED PRIME EDITING
      ◊ Precise genomic deletions using paired prime editing
      ◊ Split prime editor
      ◊ Increasing the efficiency and precision of prime editing with guide RNA pairs
  • UPDATE PRIME EDITING
      ◊ Prime editing – an update on the field
      ◊ Comprehensive analysis of prime editing outcomes in human embryonic stem cells
      ◊ Deletion and replacement of long genomic sequences using prime editing
      ◊ Prime editing – an update on the field
      ◊ Prime Editing for Human Gene Therapy: Where Are We Now?
    • PRIMARY IMMUNODEFICIENCIES
  • GENE THERAPY
      ◊ Approaches
      ◊ Gene Editing for the Treatment of Primary Immunodeficiency Diseases
      ◊ T cell gene therapy of Primary Immunodeficiency Diseases
    • PRION DISEASE
  • TREATMENT WITH RNAi
      ◊ Rescues early neuronal dysfunction and prolongs survival
  • CREUTZFELDT JAKOB DISEASE VARIANT
      ◊ Therapeutic approaches
    • PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS
  • GENE THERAPY
      ◊Current Progress of Gene Therapy for Progressive Familial Intrahepatic Cholestasis
    • PROSTAGLANDIN
  • INHIBITION IN HUMAN DISEASE
      ◊ Celecoxib and rofecoxib
    • PROSTATE CANCER
  • THERAPY
      ◊ Androgen Deprivation Therapy
    • PSORIASIS
  • THERAPEUTIC APPROACHES
      ◊ Advances
      ◊ Glut1 therapeutic target for psoriasis
      ◊ RNA-Based Antipsoriatic Gene Therapy: An Updated Review Focusing on Evidence from Animal Models
    • PULMONARY HYPERTENSION
  • GENE THERAPY
      ◊ Gene Therapy in Pulmonary Hypertension